The biotech landscape witnessed a significant milestone as Umoja Biopharma secured $100 million in its latest funding round. The Seattle-based immunotherapy startup continues to advance its groundbreaking cancer treatment technologies.
The company's innovative approach targets blood cancers and solid tumors through a unique platform that modifies T-cells. This revolutionary treatment method aims to make cancer therapy more accessible and effective for patients worldwide.
Umoja's technology stands out for its in-vivo cell therapy approach, which transforms the body into its own
Leave a Reply